A novel bivalent single-chain variable fragment (scFV) inhibits the action of tumour necrosis factor alpha.
Suppression of TNFalpha (tumour necrosis factor alpha) activity is widely considered to be among the most efficient treatments available for chronic inflammatory diseases. Here, a bivalent scFv (single-chain variable fragment) fragment, named TNF-BAb, was engineered by fusing two anti-TNFalpha scFV fragments in tandem via a long and flexible linking peptide derived from human serum albumin and produced in functional form from Escherichia coli inclusion bodies. The bioactivity assays demonstrated that TNF-BAb gained enormously in avidity and showed a much stronger ability to inhibit the biological action of TNFalpha, indicating that TNF-BAb may become a good candidate for anti-TNFalpha therapy.